IP Library › Patent Application 13896344
Patent Application
App. No. 13/896,344

METHOD OF TREATING HEMATOLOGICAL CANCERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/896,344
Abstract

Methods and compositions for treating hematological cancer are disclosed, including refractory or resistant hematological cancer.

Claims (8)

1 . Use of a compound that is a pharmaceutically acceptable salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the manufacturing of a medicament for treating hematological cancer.

2 . The use of claim 1 , wherein said hematological cancer is lymphoma.

3 . The use of claim 2 , wherein said lymphoma is B cell lymphoma.

4 . The use of claim 3 , wherein said lymphoma is diffuse large B cell lymphoma, follicular lymphoma or mantle cell lymphoma.

5 . The use of claim 1 , wherein said hematological cancer is a refractory hematological cancer.

6 . The use of claim 5 , wherein said hematological cancer is leukemia refractory to a treatment comprising one or more drugs selected from the group consisting of doxorubicin, cytarabine and fludarabine.

7 . The use of claim 5 , wherein said hematological cancer is lymphoma refractory to a regimen comprising doxorubicin or melphalan or both, or a CHOP regimen or a RCHOP regimen.

8 . The use of claim 1 , wherein said compound is sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)].

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2013
From: NIIKI PHARMA INC.
To: NIIKI PHARMA AQUISITION CORP. 2
Reel/Frame 030740/0100 →